Last reviewed · How we verify
NCT03739606
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
Phase 2 trial testing Anti-CD123/CD3 Monoclonal Antibody MGD006 in Acute Biphenotypic Leukemia. Withdrawn.
20 October 2020
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 20 October 2020 |
| Primary completion | 20 October 2020 |
| Estimated completion | 20 October 2020 |
Drugs / interventions tested
- Anti-CD123/CD3 Monoclonal Antibody MGD006 — full drug profile →
Conditions studied
- Acute Biphenotypic Leukemia — all drugs for Acute Biphenotypic Leukemia →
- Acute Leukemia — all drugs for Acute Leukemia →
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive — all drugs for Chronic Myelogenous Leukemia, BCR-ABL1 Positive →
- Hairy Cell Leukemia — all drugs for Hairy Cell Leukemia →
Sponsor
City of Hope Medical Center
Who can join
15 and older, any sex, with Acute Biphenotypic Leukemia or Acute Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as flotetuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03739606
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Biphenotypic Leukemia
Currently open trials in the same condition.
- NCT05589896 — A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantat · Phase 1, PHASE2 · recruiting
- NCT03399773 — Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukem · Phase 2 · active not recruiting
- NCT04797767 — Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms · Phase 1, PHASE2 · recruiting
- NCT04128501 — Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting · Phase 2 · active not recruiting
- NCT03779854 — Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers · Phase 2 · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03739606 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 17 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03739606.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing